Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Woo, Hyun Seon | - |
dc.contributor.author | Kim, Hyunchul | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Ahn, Jeong Yeal | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.date.available | 2020-02-28T15:44:05Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-12 | - |
dc.identifier.issn | 1349-7006 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12081 | - |
dc.description.abstract | The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy. A total of 157 patients with newly diagnosed diffuse large B-cell lymphoma treated with 1 cycle of R-CHOP were included. Hemoglobin level without red cell transfusion within 7days of initiation of treatment was chosen as a parameter of baseline cancer-induced anemia. To investigate the clinical significance of chemotherapy-induced anemia and its recovery after completion of treatment, 87 patients in complete remission for 6months from the time of the last cycle of R-CHOP were grouped and analyzed separately. Patients with a cancer-induced anemia of hemoglobin <10g/dL showed inferior event-free and disease-free survival compared to those with hemoglobin 10g/dL. This finding was observed irrespective of the status of pre-treatment bone marrow involvement. In multivariate analysis, hemoglobin <10g/dL was found to be an international prognostic index-independent prognostic factor. Risk of relapse was significantly higher for patients who were still anemic at 6months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | CANCER SCIENCE | - |
dc.subject | NON-HODGKINS-LYMPHOMA | - |
dc.subject | CHEMOTHERAPY-INDUCED ANEMIA | - |
dc.subject | CANCER | - |
dc.subject | RITUXIMAB | - |
dc.subject | NEUTROPENIA | - |
dc.subject | PARAMETERS | - |
dc.subject | THERAPY | - |
dc.subject | ALPHA | - |
dc.subject | DEATH | - |
dc.title | Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000346347600007 | - |
dc.identifier.doi | 10.1111/cas.12544 | - |
dc.identifier.bibliographicCitation | CANCER SCIENCE, v.105, no.12, pp.1569 - 1575 | - |
dc.identifier.scopusid | 2-s2.0-84917735143 | - |
dc.citation.endPage | 1575 | - |
dc.citation.startPage | 1569 | - |
dc.citation.title | CANCER SCIENCE | - |
dc.citation.volume | 105 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.contributor.affiliatedAuthor | Woo, Hyun Seon | - |
dc.contributor.affiliatedAuthor | Kim, Hyunchul | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.contributor.affiliatedAuthor | Ahn, Jeong Yeal | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Anemia | - |
dc.subject.keywordAuthor | biomarkers | - |
dc.subject.keywordAuthor | diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | non-Hodgkin&apos | - |
dc.subject.keywordAuthor | s lymphoma | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | CHEMOTHERAPY-INDUCED ANEMIA | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | NEUTROPENIA | - |
dc.subject.keywordPlus | PARAMETERS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ALPHA | - |
dc.subject.keywordPlus | DEATH | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.